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Abstract: A key factor in determining the likely outcome for a patient with colorectal cancer is whether
or not the tumour has metastasised to the lymph nodes—information which is also important in
assessing any possibilities of lymph node resection so as to improve survival. In this review we
perform a wide-range assessment of literature relating to recent developments in gene expression
profiling (GEP) of the primary tumour, to determine their utility in assessing node status. A set
of characteristic genes seems to be involved in the prediction of lymph node metastasis (LNM) in
colorectal patients. Hence, GEP is applicable in personalised/individualised/tailored therapies and
provides insights into developing novel therapeutic targets. Not only is GEP useful in prediction of
LNM, but it also allows classification based on differences such as sample size, target gene expression,
and examination method.
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1. Introduction
Colorectal cancer (CRC) is one of the most common causes of cancer-related deaths worldwide [1].
Currently, CRC patients are classified by staging of the tumours with the tumour/node/metastases
(TNM) system validated by the American Joint Committee on Cancer (AJCC). In this system,
patients are divided into various groups and subgroups, according to the size and extension of
the primary tumour, its lymphatic involvement, and any metastatic features. Usually, advanced
cancer stages are characterised by metastases to local lymph nodes (LNs) or other organs, which lead
to poor prognosis [2]. Among the criteria included in the TNM system, LNs are the strongest
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predictive/prognostic marker for evaluating patient outcomes and choosing the best therapeutic
strategy [3,4].
Curative surgery improves the CRC patient’s status at least in early stage, but the healing process
is not adequate by itself [5]. For example, five-year survival rates published by the American Cancer
Society (ACS) are highly variable: 74% for stage I, 67% for stage IIA, 59% for stage IIB, 37% for
stage IIC, 73% for stage IIIA, 46% for stage IIIB, 28% for stage IIIC, and 6% for stage IV disease
(https://www.verywell.com, Updated 9 April 2017). In another report, nearly 30% of CRC cases with
no record of their lymph node metastasis (LNM) status were found during the five-year follow-up to
have died because of tumour recurrence. The authors of the latter study concluded that the presence of
the occult lymph node metastases (micrometastases) that were not detected by routine examinations
might be the cause [6].
The prevalence of micrometastases in patients with early CRC has recently been widely
investigated. Published data indicate that even patients with stage I, who seem to have localised
disease, may harbor micrometastases that were missed during the clinicopathological tests [7]. In line
with this finding, Bonetti et al. (2011) showed that the occurrence of micrometastases was the main
cause of death in patients with early-stage cancer [8]. Therefore, LN involvement has to be considered
as a key factor in overall survival (OS) and disease-free survival (DFS). Thus, it may be also necessary
to use molecular techniques to enhance this evaluation. In this paper, the role of gene expression
profiling (GEP) in predictions of occult lymph node metastasis in colorectal cancer is reviewed.
2. Pathogenesis of CRC
Like other cancer types, CRC occurs by multiple misregulation of oncoproteins or tumour
suppressors that impair the intra- and extra-cellular signal balances. The two most applicable models
in this field are as follows:
(1) A model that consists of three molecular subtypes including:
(a) chromosomal instability (CIN) [9],
(b) CpG island methylator phenotype (CIMP) [10],
(c) microsatellite instability (MSI) [11].
(2) A model of four consensus molecular subtypes (CMSs). The members of this model show the
following discriminating features:
(a) CMS1 (14%), microsatellite instability (MSI) and immune hyperactivation,
(b) CMS2 (37%), epithelial involvement, wingless-type MMTV integration site family member
(WNT) and MYC pathway interaction,
(c) CMS3 (13%), epithelial and metabolic involvement,
(d) CMS4 (23%), invasive and metastatic activation of transforming growth factor–β
(TGF-β) [12].
These models facilitate the identification of germline mutations of the genes involved in DNA
mismatch repair (MMR) including MutS protein homolog 2 and 6 (MSH 2,6), MutL protein homolog 1
(MLH1), and PMS1 homolog 2 (PMS2), which all cause MSI in patients with hereditary HNPCC/Lynch
syndrome [13]. As in Model 1, the CIN approach help us to characterise the 85% of CRC cases with
enhanced chromosomal gains (1q, 7p-q, 8q, 13q and 20p-q) and losses (8q21-pter, 15q11-15, 17p12-13,
18q12-21) [14–16]. In addition, 12 subsets of mutated genes have been identified that can trigger the
cancer initiation [17]. Among them, the adenomatous polyposis coli (APC) mutation is the most
frequent initiating event during the cell transformation. APC mutation by dysplastic aberrant crypt
foci results in Wnt/β-catenin signaling pathway activation [18]. The subsequent changes may occur
in Kirsten RAS (K-RAS) and tumour suppressor p53 protein. For example, the transition of colonic
polyps into the tumour process is boosted by mutated K-RAS or p53 [19,20]. Besides the Wnt signaling
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cascade, TGF-β signaling intermediates including Sma and Mad-related protein 2 and 4 (SMAD 2,4),
Runt-related transcription factor 3 (RUNX3), and Thrombospondin 1 (TSP1) are highly misregulated
during CRC [21].
3. Gene Expression Profiling
As previously mentioned, DNA mutations have a huge impact on prognosis and survival rates.
However, the impact of thousands of detected mutations on cancer progression has not yet been
elucidated, and we are not sure whether some of these mutations cause the cancer (driver mutations)
or emerge because of the cancer (passenger mutations). Currently, gene expression profiling of the
primary tumours has received a great deal of attention due to its ability to create a detailed picture of
the genetic and epigenetic alteration status of tumours.
What is the actual value of the gene expression signatures for the prediction of key events such
as recurrence or LNM in CRC patients? This question has been the subject of numerous previous
studies (Table 1 and Supplementary Material). Generally, these studies have shown that GEP is capable
of evaluating the expression of numerous genes in a single test, thereby allowing a highly accurate
depiction of cell function and status. The obtained expression pattern may be used to classify cells
based on their function, type, or response to specific reagents [20].
Table 1. Summary of published reports on gene expression profiling (GEP) in colorectal cancer (CRC)
patients during 2004–2018.
References Samples/Method Panel Conclusion
Arango et al. (2005) [22] 137 fresh-frozen tumour StageIII CRC/Microarray analysis 22,283 probe sets GEP predict recurrence in Dukes’ C
Bertucci et al. (2004) [23]
50 cancerous and
noncancerous colon
tissues/Microarray analysis
The panel of ~8000 genes
(spotted human cDNA)
GEP can improve the
prognostic markers
Watanabe et al. (2011) [24] 141 CRC patientsMicroarray analysis 40 discriminating probes
18 genes found to decrease in
patients with lymph node
metastasis (LNM) in comparison to
those without metastases
Watanabe et al. (2009a) [25] 89 CRC Patients/Human U133Plus 2.0 GeneChip® 73 novel discriminating genes
GEP may be useful in predicting the
presence of LNM
Watanabe et al. (2009b) [26]
36 stage III CRC
patients/Human U133 Plus
2.0 GeneChip®
The genes that are predictive
for the presence of lymph
node metastasis
GEP is useful in predicting
recurrence in stage III
colorectal cancer
Wang et al. (2004) [27]
74 patients with Dukes’ B
CRC/Microarray
U133a GeneChip®
Containing a total of
22,000 probe sets
A 23-gene signature that predicts
recurrence in Dukes’ B patients
Salazar et al. (2010) [28]
188 fresh-frozen tumour with
stage I to IV CRC/Agilent 44
K oligonucleotide arrays
- Coloprint can distinguish low- andhigh-risk patients 18 genes
Meeh et al. (2009) [29]
25 fresh-frozen CRC
tumour/Digital long serial
analysis of gene expression
Sequenced to a depth of
26,060 unique tags
Development of LN in CRC occurs
in part through elevated epithelial
FN1 expression
Lenehan et al. (2012) [30]
74 CRC patients
(FFPE)/TaqMan
Low-Density Arrays
225 prespecified tumour genes
Onco-Defender-CRC capable of
differentiating between patients at
“high risk” from those at “low risk”
Kwon et al. (2004) [31] 12 fresh-frozen CRCtumour/Microarray analysis 408 genes GEP can predict LNM
Marisa et al. (2013) [32]
750 fresh-frozen CRC
samples/Human U133 Plus
2.0 eneChip®
6 subtypes (Each contains
1000 genes)
GEP makes it possible to classify
CRC samples based on genetic
signatures and identify the targets
for therapeutic attempts
Becht et al. (2016) [33] 1388 CRC tumoursamples/Microarrays analysis -
GEP is applicable in immune and
stromal classification of
CRC tumours
Inoue et al. (2015) [34] One hundred FFPE tissueSamples/Microarrays analysis -
GEP could explain the heterogeneity
of unresectable advanced or
recurrent CRC
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Table 1. Cont.
References Samples/Method Panel Conclusion
Vishnubalaji et al. (2015) [35]
13 fresh-frozen consecutive
sporadic CRCs matched with
their adjacent normal
mucosa/microarray chip and
miRNA microarray chip
Genes involved in pathways
of cell cycle, integrated cancer
The data revealed several hundred
potential miRNA-mRNA regulatory
networks in CRC and suggest
targeting relevant networks as
potential therapeutic strategy
for CRC
Yamada et al. (2018) [36]
278 colorectal tissue
samples/Real-time RT-PCR,
cell culture, and RNA
Panel of lnc-RNAs
The data highlight the capability of
RNA-seq to discover novel
lncRNAs involved in human
carcinogenesis, which may serve as
alternative biomarkers and/or
molecular treatment targets
Nguyen et al. (2015) [37]
The 1358 unique patients of six
different CRC data
sets/Microarray analysis
Panel of CRC-113
gene signature
CRC-113 gene signature provides
new possibilities for improving
prognostic models and personalised
therapeutic strategies
Gao et al. (2015) [38] 1005 patients with stage IICRC/Microarray analysis
Eight cancer hallmark–based
gene signatures were
identified to construct CSS
(cancer-specific survival)
(cancer-specific survival) sets
for determining prognosis
The prediction accuracy for low-and
high-risk disease significantly
outperformed other gene signatures
such as Oncotype DX and ColoPrint
Li et al. (2017) [39]
11 primary colorectal
tumours/Single-cell
RNA-Seq Method
Panel of 292 genes
Results demonstrate that unbiased
single-cell RNA-Seq profiling of
tumour and matched normal
samples enables us to characterise
aberrant cell states within a tumour
The detection of high-risk patients with recurrent CRC is arguably the main challenge.
In this regard, applying molecular assessment tools could be helpful in identifying cases of occult
micrometastasis and potential suitability of adjuvant therapy [40,41]. Accordingly, new molecular
approaches are required for rapid and accurate detection of occult lymph node metastasis.
Over the last decade, gene expression profiling by microarray has been a pioneering method in
the detection of disease-related molecules. Compared with other standard techniques such as RT-PCR,
which is not able to evaluate a large number of targets at once, microarray screening provides fast and
reliable data with high accuracy from various samples. With microarray, it is now possible to analyse
the whole expression pattern of a human genome within 48–72 h, thus gathering precious details about
related molecular subtypes [42].
Using cDNA microarray technology, Kwon et al. (2004) examined and compared the expression
profiling of 4608 genes in 12 CRC tumours versus in noncancerous tissues [31]. According to their
report, 120 genes that regulate cell signalling, metabolism, proliferation, and apoptosis were expressed
differently between the experimental groups.
Wang et al. (2004) tried to identify new prognostic markers for cancer relapse by DNA chip
technology. Their achievement was a 23-gene panel allowing prediction of recurrence in Dukes’
B patients. The panel also provided insight regarding the underlying biological mechanism of
rapid metastases; some of these genes are involved with tumour development and cell proliferation.
For example, Tyrosine 3 mono-oxygenase tryptophan 5-monooxygenase activation proteins (YWHAH)
and Regulator of chromosome condensation 1 (RCC1) are the most important genes governing the G2
checkpoint of the cell cycle and chromosome condensation initiation, respectively [27]. In the same year,
Bertucci et al. (2004) compared 50 cancerous and noncancerous colonic tissues using a DNA microarray
consisting of ~8000 spotted human cDNAs, in the process discovering that Guanine nucleotide binding
protein subunit beta2 like-1 (GNB2L1), also named as RACK1, was the top-ranked gene overexpressed
in cancer samples [23]. The product of this gene is a homologue of the beta subunit of G proteins,
and participates in signal transduction and Protein Kinase C (PKC) activation. They also evaluated the
Nucleoside diphosphate kinase A (NM23) level and noted that in NM23-positive patients, the chance
of metastasis and death is significantly less than in the NM23-negative cases [23].
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Arango et al. (2005) proved that the downregulation of Ras homolog gene, a small GTPase protein
known to regulate the actin cytoskeleton, was correlated with shorter survival. This approach is not
only useful in Dukes’ C patients’ recurrence predictions but also can be used in the design of clinical
management algorithms [22].
Meeh and colleagues used digital long serial analysis of gene expression to elucidate the
differences between node-negative and node-positive colorectal tumours. They reported that the
development of node-positive CRC occurs, in part, through elevated levels of epithelial Fibronectin 1
(FN1). They suggested that the progression of the CRC from node-negative to node-positive disease
may be facilitated partially by FN1 deregulation and the subsequent enhancement of tumour cell
migration [29].
In 2009, Watanabe and colleagues determined that gene expression programming could be a
useful tool in predicting recurrence in stage III colorectal cancer, and also identified calcineurin binding
protein 1 (CABIN1) among discriminating genes that may play a key role in the development of
recurrence [26]. Additionally, they identified 73 novel genes and transcripts the expression of which
varied significantly between patients with or without LNM. Of these, 37 genes were upregulated and
36 showed lower expressions in cases with LNM compared with patients without LNM. The list of
genes included tumour suppressor genes (ST7, BAP1) and transmembrane glycoprotein related to
lymph node metastasis in prostate cancer (PSMA) [25].
The other family involved in cancer metastasis is the Forkhead box proteins (FOX). For example,
FOXC2, also known as Forkhead Box C2 (FKHL14), has been found to be significantly elevated in
patients with lymph node involvement and correlated with the degree of LNM [32]. Upregulation of
the other member of this family, FOXP3, is linked with depression of the immune response by the
accelerating the secretion of factors like TGF-β and Interleukin-10 [43].
In 2011, Salazar and colleagues developed a robust gene expression classifier (ColoPrint) that can
predict relapses in patients with early-stage CRC. According to their study, this method can identify
patients with stage II CRC who will experience a recurrence within five years after surgery [28].
The technique is not only able to predict the development of distant metastasis but also helps to
identify the individuals who may be safely managed without chemotherapy independent of the
clinical variables [30,44].
Besides ColoPrint, Lenehan et al. (2012) have developed a molecular prognostic examination
able to identify tumour recurrence within three years in CRC cases having curative surgery.
From analysing the expression changes of 18 key genes involved in regulation of cell signal
transduction, gene expression, invasion, growth, angiogenesis, apoptosis, and antioxidation,
they identified five genes that could be used in the prediction of tumour recurrence in CRC patients:
BMI-1 polycomb ring finger oncogene (BMI), Vascular endothelial growth factor A (VEGFA), Ribosomal
protein S10 (RPS10), Ets variant 6 (ETV6), and H3 histone, family 3B (H3F3B). However, the test was
validated in stage I and II patients and the authors concluded that ≥12 lymph node samples would be
required for accurate prognostication [30].
The results of another study on 196 genes in CRC patients determined that use of the expression
pattern of main genes such as Annexin A3 (ANXA3), C-type lectin domain family 4 member M
(CLEC4D), Lamin B (LMNB1), proline rich and Gla domain 4 (PRRG4), TNF alpha induced protein 6
(TNFAIP6), Lamin B1 (TNFAIP6), Vanin 1 (VNN1), and Interleukin 2 receptor subunit beta (IL2RB)
that participate in tumour initiation and development could act as novel biomarkers for early detection
of CRC [35]. In line with these findings, Ganepola (2014) proposed that gene expression signatures of
Oncotype DX and ColoPrint could be good tools for management of early-stage colon cancer [45].
GEP has been investigated for its potential to predict the outcome of patients in other cancers, too.
Méndez et al. (2011) identified five genes (Receptor accessory protein (1REEP1), Ring finger protein
145 (RNF145), CTONG2002744, Myosin VA (MYO5A), and FBXO32) that were differentially expressed
between node-positive and node-negative oral squamous cell carcinomas (OSCC), and suggested
that this model is applicable for identification of occult metastasis in patients [46]. Similarly,
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studies on primary lung adenocarcinomas, pancreatic, breast, bladder, and prostate cancers models
depicted a marked alteration in gene expression patterns along with a high relative risk of nodal
involvement [47–51]. 4. The Limitations of the GEP Approach
As already discussed, the GEP platform provides a unique opportunity to examine tens of
thousands of different candidate genes at a given time. However, like other laboratory methods,
GEP technology is limited. The data obtained from GEP are very simple and only consist of the
candidate genes. GEP is not able to detect the interactions or signaling crosstalks. Therefore, other data
analyses must be performed to elucidate the underlined network, for example, behind the antitumour
drug resistance. Thus, different perceptions may be derived from a single raw data point. The other
limitation of the GEP approach is the sample type and the method of preparation. The DNA of
different types of cells and tissues of the body undergo multiple modifications and express various
genes; hence, the quality of DNA extraction and isolation is directly related to the GEP output.
This noise is usually resolved by increasing the sample size, but in particular cases, other alternatives
such as RNA sequencing technology [52,53] or single-cell RNA sequencing (scRNA-Seq) [44] should
be considered, subsequently.
4. Conclusions
Overall, for prediction of tumour recurrence and metastasis, GEP analysis has marked advantages
compared to routine clinical exams. Using microarray technology, various genes are identified that
allow prediction of LNM in CRC cases. Based on this approach, a new classification of CRC has been
introduced that reflects the different biological pathways and distinct prognostic features, allowing
preselection of patients who would benefit from adjuvant therapies. However, more investigations are
also needed to identify the genes associated with poor prognosis profiles, since these may actually
prove interesting potential targets for rational development of new cancer drugs.
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